<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Pulm Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Pulm Med</journal-id>
      <journal-title-group>
        <journal-title>BMC Pulmonary Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2466</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24885608</article-id>
      <article-id pub-id-type="pmc">4027997</article-id>
      <article-id pub-id-type="publisher-id">1471-2466-14-83</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2466-14-83</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Wang</surname>
            <given-names>Qiushi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>wqsdpbl@163.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>He</surname>
            <given-names>Yong</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>heyong8998@126.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Yang</surname>
            <given-names>Xin</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>32317432@qq.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Wang</surname>
            <given-names>Yubo</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>wangyubo_110@163.com</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A5">
          <name>
            <surname>Xiao</surname>
            <given-names>Hualiang</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>dpbl_xhl@126.com</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Pathology, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China</aff>
      <aff id="I2"><label>2</label>Department of Respiration, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>5</month>
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <fpage>83</fpage>
      <lpage>83</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>3</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>5</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Wang et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Wang et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2466/14/83"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>The discovery of the fusion gene echinodermmicro tubule associated proteinlike 4-anaplastic lymphoma kinase, EML4-ALK, in patients with non-small-cell lung cancer has led to the remarkable development of anaplastic lymphoma kinase inhibitors, such as crizotinib. Consequently, the clinical outcomes of these patients have improved dramatically. Herein, we report the case of a woman with <italic>ALK</italic> gene translocation-squamous cell lung cancer who experienced a remarkable tumor response to crizotinib after two courses of failed chemotherapy.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 55-year-old Chinese woman was diagnosed with cervical lymph node metastatic squamous carcinoma. Chest computed tomography scan showed the primary tumor in the lower lobe of the right lung. The patient had received two successive courses of first-line chemotherapy without tumor response. Tumor cells were negative for wild-type of epidermal growth factor receptor/K-RAS variants; thus, she was not eligible for tyrosine kinase inhibitor therapy. Unfortunately, increased levels of interleukin-6 and carcinoembryonic antigen, and computed tomography scan results indicated cancer progression. Once crizotinib was approved by the China Food and Drug Administration and the <italic>ALK</italic> gene translocation was identified in tumor cells by fluorescent in situ hybridization, the patient commenced treatment with crizotinib. Remarkably, the tumor response to crizotinib was classified as partial response after only 26&#xA0;days of treatment commencement. The partial response status has been maintained to date (23&#xA0;weeks).</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Considering this remarkable response to crizotinib, we can safely conclude that patients with squamous cell lung cancer should have the option of undergoing <italic>ALK</italic> testing to determine if there is indication for crizotinib treatment even after they have failed chemotherapy.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>
          <italic>ALK</italic>
        </kwd>
        <kwd>Crizotinib</kwd>
        <kwd>Squamous cell lung cancer</kwd>
        <kwd>Chemotherapy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Treatment of EML4-ALK fusion-positive non-small-cell lung cancer (NSCLC) with the anaplastic lymphoma kinase (ALK)-targeted agent, crizotinib, offers significant improvement of clinical outcomes
[<xref ref-type="bibr" rid="B1">1</xref>]. Herein, we report the successful case of a patient with squamous cell lung cancer and ALK gene translocation that experienced a remarkable response to crizotinib treatment after two courses of failed chemotherapy.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 55-year-old woman presented in May 2013 with cough, sputum, and annihilation after activities of daily living, for more than 20&#xA0;days. She had no history of smoking or alcoholism, but had undergone total hysterectomy because of hysteromyoma in 2010. She was diagnosed with hypertension three years earlier. On physical examination, an enlarged right cervical lymph node was palpated. Chest computed tomography (CT) scan (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>A) indicated the presence of a mass in the lower lobe of the right lung and mediastinal lymph node enlargement. The patient was then accepted and treated by the Department of Respiration for lung cancer stage IV with cervical lymph node metastasis (T4N3M1).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Chest computed tomography (CT) scans.</bold> Before the first chemotherapy treatment (May 2013) <bold>(A)</bold>. After the second course of chemotherapy <bold>(B)</bold>. After 26&#xA0;days <bold>(C)</bold> and 11&#xA0;weeks <bold>(D)</bold> of crizotinib treatment.</p>
        </caption>
        <graphic xlink:href="1471-2466-14-83-1"/>
      </fig>
      <p>The whole enlarged right cervical lymph node was resected, and followed by biopsy and histologic examination. Hematoxylin and eosin (H &amp; E) staining showed the typical morphology of squamous cell carcinoma cells (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>A and B). Immunohistochemistry (IHC) analysis demonstrated that tumor cells were positive for cytokeratin (CK) 5/6 (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>C) and P63 (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>D), and negative for CK7, CK20, TTF-1, and Napsin A. The positive rate of Ki-67 was 30%. Altogether, these results confirmed the diagnosis of metastatic squamous cell carcinoma. The patient requested treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) because dozens of patients with squamous cell carcinoma and EGFR mutations responded well to TKIs at our institute. Amplification refractory mutation system (ARMS) was used to assess EGFR and K-RAS gene profiles to determine the presence of mutated variants. However, evidence of a normal genotype excluded the patient from receiving EGFR-TKI treatment.</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Right cervical lymph node analysis.</bold> H &amp; E staining <bold>(A and B)</bold>. IHC staining of CK5/6 <bold>(C)</bold>, P63 <bold>(D)</bold>, and ALK (1A4) <bold>(E)</bold>. <italic>ALK</italic> gene translocation (FISH, arrows: split-apart signals for <italic>ALK</italic> gene translocation) <bold>(F)</bold>.</p>
        </caption>
        <graphic xlink:href="1471-2466-14-83-2"/>
      </fig>
      <p>As first-line chemotherapy, the patient was initially administered 135&#xA0;mg/m<sup>2</sup> (210&#xA0;mg) of paclitaxel and 80&#xA0;mg/m<sup>2</sup> (120&#xA0;mg) of nedaplatin. During treatment, the patient&#x2019;s condition did not seem to improve; thus, after a 20-day treatment, a second round of chemotherapy was administered with 75&#xA0;mg/m<sup>2</sup> (120&#xA0;mg) of docetaxel and 80&#xA0;mg/m<sup>2</sup> (120&#xA0;mg) of nedaplatin. Unfortunately, increasing levels of interleukin-6 (IL-6) (25.41 vs 16.03&#xA0;pg/mL) and carcinoembryonic antigen (CEA) (23.43 vs 7.13&#xA0;ng/mL) indicated cancer progression, which was confirmed by the presence of multiple metastases in both lungs on CT scan images (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>B). Although not initially indicated, the patient was then administered oral treatment with the EGFR-TKI, erlotinib (1-month trial). However, this treatment showed no efficacy.</p>
      <p>After the use of crizotinib was approved by the China Food and Drug Administration (CFDA) in July 2013, the patient underwent <italic>ALK</italic> testing. IHC staining (<italic>Clone 1A4</italic>, <italic>Origene</italic>, 1:200) showed tumor cell positivity for ALK protein (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>E). Then <italic>ALK</italic> break-apart fluorescent in situ hybridization (FISH) was performed on 4-&#x3BC;m, formalin-fixed, paraffin-embedded tissue sections. Slides were hybridized with the LSI <italic>ALK</italic> Break Apart Rearrangement Probe (Vysis, Abbott Molecular, Des Plaines, IL, USA), and read on an epifluorescence microscope (BX41, Olympus, Tokyo, Japan). The lung cancer cell line, NCI-H2228, (American Type Culture Collection-ATCC) was used as positive control. At least 50 tumor cell nuclei were analyzed and at least 15% of interpretable tumor cells harboring break-apart signals were used as the cutoff value
[<xref ref-type="bibr" rid="B2">2</xref>]. As a result, the presence of <italic>ALK</italic> gene translocation was confirmed (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>F).</p>
      <p>The patient underwent crizotinib treatment (250&#xA0;mg/bid, orally) for 26&#xA0;days. After this period, symptoms, including neck constriction and cough, were improved. Chest CT scan images demonstrated decrease in tumor size and metastases. According to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1), such tumor response to crizotinib was classified as partial response (PR) (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>C). Follow-up chest CT scan performed 11&#xA0;weeks after the beginning of the treatment revealed a dramatic reduction in tumor size and mediastinal lymph node, with nearly no presence of metastases in both lungs (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>D). IL-6 (3.34 vs 25.41&#xA0;pg/mL) and CEA (1.84 vs 23.43&#xA0;ng/mL) levels were also reduced 23&#xA0;weeks after the beginning of the therapy, which demonstrated continuous partial response.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>According to the National Comprehensive Cancer Network guidelines, <italic>ALK</italic> testing is not routinely performed in patients with squamous cell lung cancer. Therefore, this patient was not tested for <italic>ALK</italic> until crizotinib was approved for marketing by the CFDA (June 23, 2013). Unfortunately, neither chemotherapy nor EGFR-TKI treatment produced effective tumor response in this patient.</p>
      <p><italic>ALK</italic> gene translocations have been previously detected in patients with lung adenocarcinoma and light or non smoking history
[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. To date, two studies have previously reported cases of patients with mixed carcinoma and squamous cell component harboring <italic>ALK</italic> rearrangements
[<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>], but these studies did not describe specific therapy or diagnostic procedures. Another report showed that a patient with squamous cell lung cancer, harboring c-MET amplification, had partially responded to crizotinib
[<xref ref-type="bibr" rid="B7">7</xref>]. Herein, we report the case of a non-smoking woman with squamous cell lung cancer and <italic>ALK</italic> gene rearrangement who experienced remarkable response to crizotinib treatment after failed chemotherapy. In concordance with other studies on patients with lung adenocarcinoma treated with crizotinib
[<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>], this patient has remained in remission (PR). Most importantly, such remarkable response was obtained after two courses of failed chemotherapy.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>Despite the low reconstruction rate of <italic>ALK</italic> gene, if applicable, patients with squamous cell lung cancer should have the option of undergoing <italic>ALK</italic> testing and receiving crizotinib treatment. <italic>ALK</italic> testing and subsequent targeted therapy could be an effective option for patients with non-small cell lung cancer who present progression following chemotherapy, radiotherapy, or any other treatment.</p>
      <sec>
        <title>Consent</title>
        <p>The patient provided written consent for publication of this case report.</p>
      </sec>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>EML4: Echinodermmicro tubule associated protein like 4; ALK: Anaplastic lymphoma kinase; NSCLC: Non-small-cell lung cancer; CT: Chest computed tomography; TKIs: Tyrosine kinase inhibitors; EGFR: Epidermal growth factor receptor; IL-6: Interleukin-6; CEA: Carcinoembryonic antigen; CFDA: China Food and Drug Administration; FISH: Fluorescent in situ hybridization; PR: Partial response; IHC: Immunohistochemistry; H &amp; E: Hematoxylin and eosin; ARMS: Amplification refractory mutation system; RECIST: Response Evaluation Criteria in Solid Tumors.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>QSW carried out the molecular identifications of EGFR and K-ras, and drafted the manuscript. YH provided parts of the clinical treatment data and revised the manuscript. XY participated in the H &amp; E, IHC, and FISH analyses. YBW provided parts of the clinical treatment data. HLX participated in the design and coordination of this study, and helped to revise the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2466/14/83/prepub">http://www.biomedcentral.com/1471-2466/14/83/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>We would like to thank Li Lin for the assistance on IHC analysis. We would also like to thank Edanz Editing for language revision of the manuscript.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Djalalov</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Beca</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hoch</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Krahn</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tsao</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Cutz</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Leighl</surname>
            <given-names>NB</given-names>
          </name>
          <article-title>Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2014</year>
          <volume>32</volume>
          <issue>10</issue>
          <fpage>1012</fpage>
          <lpage>1019</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2013.53.1186</pub-id>
          <pub-id pub-id-type="pmid">24567430</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rodig</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Mino-Kenudson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dacic</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yeap</surname>
            <given-names>BY</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Barletta</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Stubbs</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Law</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Lindeman</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Mark</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Janne</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Lynch</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>BE</given-names>
          </name>
          <name>
            <surname>Iafrate</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Chirieac</surname>
            <given-names>LR</given-names>
          </name>
          <article-title>Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population</article-title>
          <source>Clin Cancer Res</source>
          <year>2009</year>
          <volume>15</volume>
          <fpage>5216</fpage>
          <lpage>5223</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0802</pub-id>
          <pub-id pub-id-type="pmid">19671850</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shaw</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Yeap</surname>
            <given-names>BY</given-names>
          </name>
          <name>
            <surname>Solomon</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Riely</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Gainor</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Engelman</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Shapiro</surname>
            <given-names>GI</given-names>
          </name>
          <name>
            <surname>Costa</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Ou</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Butaney</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Salgia</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Maki</surname>
            <given-names>RG</given-names>
          </name>
          <name>
            <surname>Varella-Garcia</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Doebele</surname>
            <given-names>RC</given-names>
          </name>
          <name>
            <surname>Bang</surname>
            <given-names>YJ</given-names>
          </name>
          <name>
            <surname>Kulig</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Selaru</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Tang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wilner</surname>
            <given-names>KD</given-names>
          </name>
          <name>
            <surname>Kwak</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>JW</given-names>
          </name>
          <name>
            <surname>Iafrate</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Camidge</surname>
            <given-names>DR</given-names>
          </name>
          <article-title>Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis</article-title>
          <source>Lancet Oncol</source>
          <year>2011</year>
          <volume>12</volume>
          <issue>11</issue>
          <fpage>1004</fpage>
          <lpage>1012</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(11)70232-7</pub-id>
          <pub-id pub-id-type="pmid">21933749</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Inamura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Takeuchi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Togashi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Nomura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Ninomiya</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Okui</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Satoh</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Okumura</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Nakagawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Soda</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>YL</given-names>
          </name>
          <name>
            <surname>Niki</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Mano</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ishikawa</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers</article-title>
          <source>J Thorac Oncol</source>
          <year>2008</year>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>13</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e31815e8b60</pub-id>
          <pub-id pub-id-type="pmid">18166835</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wong</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>So</surname>
            <given-names>KK</given-names>
          </name>
          <name>
            <surname>Tam</surname>
            <given-names>IY</given-names>
          </name>
          <name>
            <surname>Sihoe</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Ho</surname>
            <given-names>KK</given-names>
          </name>
          <name>
            <surname>Au</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>LP</given-names>
          </name>
          <name>
            <surname>Pik Wong</surname>
            <given-names>M</given-names>
          </name>
          <article-title>The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS</article-title>
          <source>Cancer</source>
          <year>2009</year>
          <volume>115</volume>
          <fpage>1723</fpage>
          <lpage>1733</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.24181</pub-id>
          <pub-id pub-id-type="pmid">19170230</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shaw</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Yeap</surname>
            <given-names>BY</given-names>
          </name>
          <name>
            <surname>Mino-Kenudson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Digumarthy</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Costa</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Heist</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Solomon</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Stubbs</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Admane</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McDermott</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Settleman</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kobayashi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mark</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Rodig</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Chirieac</surname>
            <given-names>LR</given-names>
          </name>
          <name>
            <surname>Kwak</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>Lynch</surname>
            <given-names>TJ</given-names>
          </name>
          <name>
            <surname>Iafrate</surname>
            <given-names>AJ</given-names>
          </name>
          <article-title>Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK</article-title>
          <source>J Clin Oncol Off J Am Soc Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>4247</fpage>
          <lpage>4253</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.22.6993</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Schwab</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Petaka</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Kollar</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pinter</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Varkondi</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Kohank</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Barti-Juhasz</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Sch&#xF6;nleber</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Brauswetter</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kopper</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Urban</surname>
            <given-names>L</given-names>
          </name>
          <article-title>Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement</article-title>
          <source>Lung Cancer</source>
          <year>2014</year>
          <volume>83</volume>
          <issue>1</issue>
          <fpage>109</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lungcan.2013.10.006</pub-id>
          <pub-id pub-id-type="pmid">24192513</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Toyokawa</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Takenoyama</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Watanabe</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Toyozawa</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Inamasu</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Kojo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shiraishi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Morodomi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Takenaka</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hirai</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Yamaguchi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Taguchi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Seto</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Ichinose</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation</article-title>
          <source>J Thorac Oncol</source>
          <year>2013</year>
          <volume>8</volume>
          <issue>11</issue>
          <fpage>e96</fpage>
          <lpage>e98</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e3182a008ed</pub-id>
          <pub-id pub-id-type="pmid">24128725</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kim</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Heo</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Bang</surname>
            <given-names>YJ</given-names>
          </name>
          <article-title>Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non&#x2013;small-cell lung cancer</article-title>
          <source>J Clin Oncol</source>
          <year>2012</year>
          <volume>30</volume>
          <issue>16</issue>
          <fpage>e147</fpage>
          <lpage>e150</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2011.39.9766</pub-id>
          <pub-id pub-id-type="pmid">22508824</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
